Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAX930 (rADAMTS13) in Hereditary TTP
NCT02216084Phase 1Completed
- Sponsor
- Takeda
- Start
- Sep 2014
- Primary completion
- Feb 2016
- Modality
- Replacement Enzymes
- Countries
- 7
01
Overview
Phase 1, open-label trial of Apadamtase alfa in hereditary thrombotic thrombocytopenic purpura (hTTP) (3 cohorts), sponsored by Takeda. Primary endpoint: Occurrence of adverse events (serious and non-serious), including the incidence of binding and inhibitory antibody formation at 28 days. Started Sep 2014; status: completed.
02
Drugs
Apadamtase alfa
03
Conditions
hereditary thrombotic thrombocytopenic purpura (hTTP)
Beyond the preview
Go deeper on NCT02216084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02216084.